Cargando…

Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation

Ataxin-2 (Atx2) is a translational control molecule mutated in spinocerebellar ataxia type II and amyotrophic lateral sclerosis. While intrinsically disordered domains (IDRs) of Atx2 facilitate mRNP condensation into granules, how IDRs work with structured domains to enable positive and negative reg...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Amanjot, Hulsmeier, Joern, Kandi, Arvind Reddy, Pothapragada, Sai Shruti, Hillebrand, Jens, Petrauskas, Arnas, Agrawal, Khushboo, RT, Krishnan, Thiagarajan, Devasena, Jayaprakashappa, Deepa, VijayRaghavan, K, Ramaswami, Mani, Bakthavachalu, Baskar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946432/
https://www.ncbi.nlm.nih.gov/pubmed/33689682
http://dx.doi.org/10.7554/eLife.60326
Descripción
Sumario:Ataxin-2 (Atx2) is a translational control molecule mutated in spinocerebellar ataxia type II and amyotrophic lateral sclerosis. While intrinsically disordered domains (IDRs) of Atx2 facilitate mRNP condensation into granules, how IDRs work with structured domains to enable positive and negative regulation of target mRNAs remains unclear. Using the Targets of RNA-Binding Proteins Identified by Editing technology, we identified an extensive data set of Atx2-target mRNAs in the Drosophila brain and S2 cells. Atx2 interactions with AU-rich elements in 3′UTRs appear to modulate stability/turnover of a large fraction of these target mRNAs. Further genomic and cell biological analyses of Atx2 domain deletions demonstrate that Atx2 (1) interacts closely with target mRNAs within mRNP granules, (2) contains distinct protein domains that drive or oppose RNP-granule assembly, and (3) has additional essential roles outside of mRNP granules. These findings increase the understanding of neuronal translational control mechanisms and inform strategies for Atx2-based interventions under development for neurodegenerative disease.